Latest Content

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.

ASCO 2026: Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab monotherapy.

A large real-world analysis found that higher frailty scores were associated with increased odds of toxicities, hospitalization, and mortality in patients receiving ADC, BiTE, and CAR T-cell therapies.

A real-world study shows concurrent GLP-1 RA and ICI use may significantly improve long-term survival and lower toxicities for patients with cancer.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects.

Jenn Pouliot, MSN, RN, OCN, discusses cross-departmental hazardous drug handling protocols, 2-clinician verification mandates, and the critical role of APPs in procedural oncology settings.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Julie Elliott, MS, PA-C, reviewed clinical trial data, compared efficacy across third-line regimens, and discussed how real-world outcomes align across third-line treatment options.

The FDA approved durvalumab plus BCG for high-risk NMIBC based on significant disease-free survival gains in the POTOMAC trial.

An updated post hoc analysis showed that imetelstat nearly doubled overall survival compared with best available therapy in patients with JAK inhibitor–relapsed or refractory myelofibrosis.